News Quarterly

driving faster, better research to improve type 1 outcomes

Together, we’re leading the way for FasterCures

Earlier this month, I attended the FasterCures conference, Partnering for Cures. This conference connects hundreds of decision-makers from over 200 different disease groups who are motivated by the same mission as T1D Exchange – to reduce the time and cost of getting new therapies discovered, developed and delivered to the people who need them.

At the conference, I spoke on a panel about “Patient-Centricity” in medicine because T1D Exchange is viewed as an organization who is leading the way. (You can watch the panel on YouTube ). We aren’t just discussing how we gather the community’s input and amplify it to create better outcomes—we’re doing it, together with you through your participation in Glu , the Clinic Registry and Living Biobank .

Your efforts are going to help people with blood cancers!

In fact, our innovative approach is now being adopted by another disease group. This month, The Leukemia & Lymphoma Society (LLS) announced its partnership with Unitio – the nonprofit organization created to manage and maintain the T1D Exchange program. LLS is developing an online patient community that brings together those affected by blood cancers to share real world experiences and contribute to vital research. Sound familiar? The LLS community will use the same technology platform that currently supports Glu, it will use many of the features you've helped us create, and it will build upon many of our lessons learned.

You should be proud! The community you've helped us build to improve outcomes in type 1 diabetes will now help families touched by blood cancers connect and support each other while working together for better solutions and care.

We are excited to announce the Unitio / LLS partnership; and we remain steadfast in our commitment to accelerate the path to “FasterCures” in T1D. I am confident that working together as a community, and collaborating with our industry, advocacy and academic members, this next decade will be truly transformative

Dana A. Ball

Executive Director, T1D Exchange
CEO, Unitio

T1D Exchange Research Update: Intranasal Glucagon

Study concludes an effective alternative to glucagon injection

As you know, prompt treatment for severe low blood sugar (severe hypoglycemia) is very important. However, the current treatment for someone who is experiencing a severe low is glucagon injections—a very difficult treatment for family, friends or even bystanders to prepare and administer. A new type of glucagon is being developed by Locemia Solutions that can be given as a simple puff into the nose. With funding from The Leona M. and Harry B. Helmsley Charitable Trust, T1D Exchange developed two studies (one in adults and one in children and adolescents) to see how well glucagon given in the nose works compared with glucagon given by injection.

In the Adult study, 75 individuals had their blood sugar lowered to simulate severe hypoglycemia on two different occasions. On one occasion they received glucagon up the nose and on the other they were given glucagon by injection. On all occurrences of receipt of glucagon by injection, the participants’ blood sugar returned to normal range within 30 minutes of administration. On all but one occurrence of receipt of glucagon in the nose, participants recovered within 30 minutes of administration.

In the other study, children/adolescents had their blood sugar lowered to simulate hypoglycemia.

  • Adolescents 12-<17 years old received glucagon up the nose on one occasion and received glucagon by injection on another occasion.
  • Children 4-<12 years old received either a single occurrence of glucagon by injection or 2 occurrences of glucagon up the nose with a different dose at each occurrence.
On all occurrences of receipt of glucagon (either given up the nose or by injection), participants’ blood sugar returned to normal range within 20 minutes of administration; one participant who received glucagon up the nose blew his nose and did not return to normal range because the full dose of glucagon was not received.

Given its similarity in response and its greater ease of administration, glucagon given in the nose should be considered as a good alternative to glucagon given by injection.

How we—you and T1D Exchange—played a role in advancing intranasal glucagon

We want to congratulate two of our member companies, Lilly and Locemia Solutions, on some exciting news. Lilly has acquired Phase III Intranasal Glucagon from Locemia Solutions. Intranasal glucagon is a potential treatment for severe hypoglycemia in people with diabetes who use insulin and could be the first needle-free rescue treatment for severe hypoglycemia.

Learn more about the T1D Exchange intranasal glucagon studies in this newsletter and find out how you may have helped advance this potential treatment.

Read More

Power of the T1D Exchange Clinic Network

Our mission is to drive faster, better research to improve T1D care. A critical resource of the model is our Clinic Network.

T1D Exchange has a unified clinic network of more than 230 collaborating clinicians and coordinators from over 73 pediatric and adult sites in the US who follow more than 100,000 unique type 1 diabetes patients.

Learn why the clinic network is critical to driving better care.

T1D Exchange Biobank Samples at work!

The T1D Exchange Biobank consists of thousands of biological samples from individuals with T1D. It’s an important resources for innovative research, and promotes the exchange of knowledge and collaboration.

Three current projects are using biosamples to:

  • Identify biomarkers for diabetic retinopathy
  • Find predictors for diabetic nephropathy
  • Understand cardiovascular disease risks in diabetes.

Learn More

Opportunity for Youth Volunteers!

AYUDA seeks youth volunteers to empower diabetes communities abroad. Learn about this exciting opportunity. Time is limited!

Q4 2015

Accelerate Research: 2 Easy ways to get involved

Participate in Glu

As part of our online community of over 14,500 people touched by T1D, you can answer Question of the Day, participate in real-time research, share experiences and learn from others. Go >>

Join the Living Biobank

Help science advance research and improve lives by providing valuable blood samples from people with T1D. Go >>